Composition for improving intestinal health and function comprising milk-derived exosome as active ingredient and method for preparing same
By using milk-borne exosomes to encapsulate DNA, RNA or small molecule therapeutic agents, the problems of low and instability of exosomes are solved, and efficient delivery of intestinal drugs is achieved, especially in inflammatory bowel disease. Significant therapeutic effect.
Patent Information
- Application Number
- CN202380017582.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-08-10
- Filing Date
- 2023-01-20
- Publication Date
- 2024-11-22
AI Technical Summary
The prior art is difficult to effectively utilize exosomes as a means of drug delivery, and the low and unstable exosome production limits its large-scale production and application, especially in improving intestinal health functions.
Using milk-borne exosomes as carriers, encapsulate DNA, RNA or small molecule therapeutic agents inside them, form micropores through electroporation to improve stability and bioavailability, and locate therapeutic agents through electroporation technology Encapsulate to form an efficient intestinal drug delivery system.
High yield isolation and purification of milk-borne exosomes is achieved, ensuring stability under intense environments, improving oral bioavailability of drugs, and showing significant therapeutic effects in inflammatory bowel disease.
Smart Images

Figure CN119013003A_ABST
Abstract
Description
Technical Field
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority to Korean Patent Application No. 10-2022-0009019 filed on January 21, 2022, and Korean Patent Application No. 10-2022-0099821 filed on August 10, 2022, which are hereby incorporated by reference in their entirety.
[0003] Description of national support for research and development
[0004] This study was conducted under the management of the Korea Institute of Science and Technology (KIST) and was supported by the KIST Research and Operating Expenses Support (R&D) (Major Project Expenses) Project funded by the Ministry of Science and ICT (Project ID: 1711152094, Reverse Translational Research Program for Hyperconnected Medical Devices), the KIST Research and Operating Expenses Support (Major Project Expenses) Project funded by the Ministry of Science and ICT (Project ID: 1711173292, Personalized Diagnosis, Therapy, Regeneration, Rehabilitation, and New Drug Development), and the Innovative New Drug Basic Technology Development Project funded by the Ministry of Science and ICT (Project ID: 1711160075, Development of an Innovative siRNA Oral Therapeutic Agent for the Treatment of Inflammatory Bowel Disease).
[0005] The present disclosure relates to a composition for improving intestinal health function, which includes milk-derived exosomes as an active ingredient. Background Art
[0006] Exosomes are extracellular vesicles with a diameter of 30 to 150 nm, secreted by various types of cells. These exosomes are beginning to be used in the next generation of drug delivery technology because people realize that they play an important role in the transmission of information between cells. But the amount of exosomes secreted by cells is too small to achieve high purity, and the nature is relatively unstable, which limits their mass production. Recently, food-derived exosomes have attracted much attention. These food-derived exosomes may be readily available and generally safe. Among these exosomes, milk-derived exosomes in particular have anti-inflammatory properties and contain microRNAs that are important for mediating their pathological and physiological activities in the exosomes themselves. Milk-derived exosomes can be isolated and purified from milk at a high yield, and can maintain high stability even in the face of drastic environmental changes, such as pH or temperature. In addition, milk-derived exosomes are highly bioavailable, allowing oral administration of drugs, especially when there are lesions in the gastrointestinal tract, such as inflammatory bowel disease. Summary of the invention
[0007]
Technical issues
[0008] In one aspect, a composition for improving intestinal health function is provided.
[0009] In one aspect, a composition for improving intestinal health function is provided, wherein a therapeutic agent is localized and encapsulated in the interior space of exosomes.
[0010] In one aspect, an orally administrable composition for improving intestinal-related diseases or functions is provided.
[0011] In one aspect, a method for preparing a composition for improving intestinal health function is provided.
[0012]
Technical Solution
[0013] In one aspect, the present invention aims to provide a composition for improving intestinal health function, comprising: milk-derived exosomes; and a therapeutic agent, wherein the therapeutic agent can be DNA, RNA or a small molecule, and the therapeutic agent can be positioned and encapsulated in the space inside the exosomes.
[0014] On the other hand, a method for preparing a composition for improving intestinal health function is provided, the method comprising the following steps: (a) isolating exosomes from milk; (b) forming micropores on the surface of the exosomes by electroporating the isolated exosomes; (c) mixing the electroporated exosomes in step (b) with a therapeutic agent; and (d) removing the therapeutic agent not encapsulated in the exosomes.
[0015]
Beneficial Effects
[0016] Exosomes can be easily isolated and purified from readily available and easily accessible milk in high yields to overcome the low yield and high maintenance cost of cell-derived extracellular vesicles. In addition, instead of cell-derived extracellular vesicles with relatively unstable properties, electroporation methods can be used to encapsulate therapeutic agents into milk-derived exosomes, which have the property of maintaining high stability even under drastic environmental changes such as pH and temperature. These milk-derived exosomes have the advantage of high bioavailability, allowing oral administration of drugs, which is particularly useful when lesions are present in the gastrointestinal tract, such as in inflammatory bowel disease. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1a The expression levels of exosomal protein markers (Alix, Tsg-101, and CD9) and non-exosomal protein markers (GM130) are shown.
[0018] Figure 1b is the size distribution of milk-derived exosomes.
[0019] Figure 1c Representative TEM images of milk-derived exosomes are shown.
[0020] Figure 2a Confocal microscopy images of RAW264.7 and NCM460 cells cultured with 0.05 or 0.1 mg / mL Cy5.5-labeled Col-exo for 0, 1, 4, 8, 12, or 24 h. In this figure, the darker circles represent DAPI and the lighter circles represent Col-exo.
[0021] Figure 2b Cell proliferation rates of NCM460 and RAW264.7 cells cultured with 0, 0.1, 0.2, 0.5 or 1 mg / ml of milk-derived exosomes for 24 h are shown (n=6; ns=not significant, **p<0.01 and ****p<0.0001).
[0022] Figure 2c is a graph showing the cell viability of NCM460.
[0023] Figure 3a This is an image confirming the reduction of intracellular ROS.
[0024] Figure 3b is a graph showing the expression of mRNA encoding inflammatory cytokines in M1 macrophages (n=4; *p<0.05, **p<0.01, ****p<0.0001).
[0025] Figure 4a and 4b This is the biodistribution image of Cy5.5-labeled milk-derived exosomes. Figure 4ais a complete organ image, Figure 4b It is a cross-sectional image of an organ.
[0026] Figure 4c is a schematic diagram showing the protocol for DSS colitis induction treatment and oral administration of milk-derived exosomes.
[0027] Figure 4d Figures show (from left) weight loss, DAI changes in mice induced with DSS colitis (n≥10; ns=not significant, *p<0.05, **p<0.01 and ****p<0.0001), and colon length measured when mice were killed on day 27 (n≥10; ns=not significant, ***p<0.001 and ****p<0.0001).
[0028] Figures 5a to 5c The effectiveness of Example 1 in reducing the severity of DSS-induced colitis was demonstrated. Figure 5a are histopathological images of colon tissues analyzed by hematoxylin and eosin (H&E) staining on day 27 (○ loss of surface epithelium, ▲ ulceration, ↑ infiltration of inflammatory cells). Figure 5b are representative immunohistochemistry (IHC) images of COX-2, and arrows indicate locations where COX-2 protein is highly expressed. Figure 5c are representative images of colonic necrosis detected by TUNEL staining.
[0029] Figure 6a Shown are ROS in the colon measured by chemiluminescence assay (n≥7; ns>0.05, ***p<0.001 and ****p<0.0001).
[0030] Figure 6b Representative images of immunofluorescence (IF) staining of iNOS (blue and dark gray in the figure: DAPI; green and light gray in the figure: iNOS).
[0031] Figure 6c The expression of mRNA encoding inflammatory cytokines in colon tissues is shown (n=4; *p<0.05 and ***p<0.001).
[0032] Figure 7 is a graph showing the stability of milk-derived exosomes to the electroporation method.
[0033] Figure 8 is an image of siRNA carried in milk-derived exosomes on an agarose gel.
[0034] Fig. 9 is a graph comparing the encapsulation efficiency of siRNA in milk-derived exosomes according to electroporation variables.
[0035] Fig.10a and 10b The figure shows the visualization photograph of milk-derived exosomes encapsulating TNF-α siRNA and the relative fluorescence area size.
[0036] Fig.11 This is a diagram showing the intracellular uptake of milk-derived exosomes encapsulating TNF-α siRNA (labeled with Cy3).
[0037] Fig.12 are confocal images and fluorescence intensity graphs showing the intracellular delivery rate of milk-derived exosomes encapsulating TNF-α siRNA.
[0038] Fig.13 The graph shows the gene silencing effect (in vitro) of milk-derived exosomes encapsulating TNF-α siRNA.
[0039] Fig.14a is a schematic diagram showing the IBD induction and treatment protocol.
[0040] Fig.14b and 14c is an observation graph showing changes in body weight loss and DAI index in IBD-induced mice. DETAILED DESCRIPTION
[0041] Definition of terms
[0042] As used in this specification, the term "intracellular delivery rate" refers to the extent to which encapsulated TNF-α siRNA is delivered into cells, expressed as a percentage, by measuring the relative fluorescence intensity of TNF-α siRNA in cells relative to the relative fluorescence intensity of TNF-α siRNA in cells stained with TNF-α siRNA transfected with Lipofectamin as a reference (100%).
[0043] Hereinafter, the present invention will be described in detail.
[0044] In one aspect, the present invention is intended to provide a composition for improving intestinal health function, comprising: milk-derived exosomes; and a therapeutic agent, wherein the therapeutic agent may be DNA, RNA or a small molecule, and the therapeutic agent may be positioned and encapsulated in the space inside the exosome. In this specification, "encapsulated by being located in the internal space of the exosome" means that a substance, such as a therapeutic agent, completely enters the internal space of the exosome and is encapsulated, rather than being present only on the surface of the exosome by methods such as attachment, adsorption or adhesion.
[0045] In another aspect of the present invention, a method for improving intestinal health function of a subject is provided, the method comprising the step of administering an effective amount of milk-derived exosomes and a therapeutic agent to a subject in need thereof, wherein the therapeutic agent may be DNA, RNA or a small molecule, and wherein the therapeutic agent may be positioned and encapsulated in the internal space of the exosomes.
[0046] In another aspect of the present invention, provided is a use of milk-derived exosomes and a therapeutic agent in preparing a composition for improving intestinal health function.
[0047] In another aspect of the present invention, milk-derived exosomes and therapeutic agents for improving intestinal health function are provided.
[0048] In an exemplary embodiment, the milk may be milk of human, cow, sheep, goat, goat, camel, buffalo or yak origin, or colostrum, but is not limited thereto.
[0049] In an exemplary embodiment, the RNA may be one or more RNAs selected from the group consisting of, but not limited to, siRNA, miRNA, mRNA, shRNA, ncRNA, and antisense RNA.
[0050] In an exemplary embodiment, the siRNA may be one or more siRNAs selected from the group consisting of TNF-α siRNA, TGF-β siRNA, JAK3 siRNA, and IL-6R siRNA.
[0051] In an exemplary embodiment, the miRNA may be one or more miRNAs selected from the group consisting of Let-7b-5p, miR-320a-3p, and miR-21.
[0052] In an exemplary embodiment, the composition may be a liquid formulation and include milk-derived exosomes encapsulating the therapeutic agent at a concentration of 100 to 1000 μg / ml. Specifically, the concentration of milk-derived exosomes is 100 μg / ml or more, 150 μg / ml or more, 200 μg / ml or more, 250 μg / ml or more, 300 μg / ml or more, 350 μg / ml or more, 400 μg / ml or more, 450 μg / ml or more, or 500 μg / ml or more, and the concentration may be 1000 μg / ml or less, 950 μg / ml or less, 900 μg / ml or less, 850 μg / ml or less, 800 μg / ml or less, 750 μg / ml or less, 700 μg / ml or less, 650 μg / ml or less, 600 μg / ml or less, or 550 μg / ml or less.
[0053] In an exemplary embodiment, the composition can be a lyophilized preparation and can include milk-derived exosomes encapsulated with 0.001 to 100 wt% of a therapeutic agent based on the total weight of the composition. Specifically, those skilled in the art can adjust the content according to the concentration or solvent type of the milk-derived exosomes encapsulated with the therapeutic agent. For example, the content can be 0.001 wt% or more, 0.01 wt% or more, 0.1 wt% or more, 1 wt% or more, 5 wt% or more, 10 wt% or more, 15 wt% or more, 20 wt% or more, 25 wt% or more, 30 wt% or more, 35 wt% or more, 40 wt% or more, 45 wt% or more or 50 wt% or more, and can be 100 wt% or less, 95 wt% or less, 85 wt% or less, 80 wt% or less, 75 wt% or less, 70 wt% or less, 65 wt% or less, 60 wt% or less, or 55 wt% or less.
[0054] In an exemplary embodiment, the composition can be administered orally.
[0055] On the other hand, a method for preparing a composition for improving intestinal health function is provided, the method comprising the following steps: (a) isolating exosomes from milk; (b) forming micropores on the surface of the exosomes by electroporating the isolated exosomes; (c) mixing the electroporated exosomes in step (b) with a therapeutic agent; and (d) removing the therapeutic agent not encapsulated in the exosomes.
[0056] In an exemplary embodiment, the electroporation of step (b) may apply a voltage of 250 to 350 V. Specifically, the voltage may be 250 V or more, 255 V or more, 260 V or more, 265 V or more, 270 V or more, 275 V or more, 280 V or more, 285 V or more, 290 V or more, 295 V or more, or 300 V or more, and may be 350 V or less, 345 V or less, 340 V or less, 335 V or less, 330 V or less, 325 V or less, 320 V or less, 315 V or less, 310 V or less, or 305 V or less.
[0057] In an exemplary embodiment, the electroporation of step (b) may be applied 3 to 7 pulses. Specifically, the pulses may be 3 or more, 4 or more, 5 or more, and may be 7 or less, or 6 or less.
[0058] In an exemplary embodiment, the electroporation of step (b) can apply a pulse of 20 to 40 ms time period. Specifically, the pulse can be 20 ms or longer, 21 ms or longer, 22 ms or longer, 23 ms or longer, 24 ms or longer, 25 ms or longer, 26 ms or longer, 27 ms or longer, 28 ms or longer, 29 ms or longer, or 30 ms or longer, and can be 40 ms or shorter, 39 ms or shorter, 38 ms or shorter, 37 ms or shorter, 36 ms or shorter, 35 ms or shorter, 34 ms or shorter, 33 ms or shorter, 32 ms or shorter, or 31 ms or shorter.
[0059] In an exemplary embodiment, the milk of step (a) may be milk of human, cow, sheep, goat, goat, camel, buffalo or yak origin, or may be colostrum.
[0060] In an exemplary embodiment, the therapeutic agent of step (c) may be DNA, and step (d) may be the addition of a deoxyribonuclease to remove unencapsulated therapeutic agent.
[0061] In an exemplary embodiment, the therapeutic agent of step (c) can be RNA, and step (d) can be the addition of a ribonuclease to remove unencapsulated therapeutic agent.
[0062] In an exemplary embodiment, the RNA of step (c) may be one or more RNAs selected from the group consisting of siRNA, miRNA, mRNA, iRNA, ncRNA, and antisense RNA.
[0063] In an exemplary embodiment, the siRNA of step (c) may be one or more siRNAs selected from the group consisting of TNF-α siRNA, TGF-β siRNA, JAK3 siRNA, and IL-6R siRNA.
[0064] In an exemplary embodiment, the miRNA of step (c) may be one or more miRNAs selected from the group consisting of Let-7b-5p, miR-320a-3p, and miR-21.
[0065] Hereinafter, the present invention will be described in more detail with reference to exemplary embodiments. These embodiments are intended only to illustratively describe the present invention, and the scope of the present invention is not limited by these embodiments. Any configuration that is substantially the same as the technical essence disclosed in the claims of the present invention in configuration and operational effect belongs to the technical scope of the present invention.
[0066] Example
[0067] 1. Confirmation of the effectiveness of bovine colostrum-derived exosomes in the prevention and treatment of inflammatory bowel disease
[0068] (1) Cell culture
[0069] NCM460 cells and RAW264.7 cells (40071, Korean cell line bank) were grown in Dulbecco's modified eagle's medium (DMEM) containing high glucose (SH30243.01, Hyclone, USA), the medium containing 10% fetal bovine serum (FBS, FP-0500-A, Atlas Biologicals, USA) and 1% antibiotic-antimycotic (15240096, ThermoFisher Scientific, USA). Cells were cultured in a 37°C incubator containing 5% carbon dioxide (CO2). To induce M1-like macrophages, RAW264.7 cells were stimulated with 100 ng / ml LPS (L4524, Sigma, USA) and 20 ng / ml IFN-γ (315-05, PeproTech, UK) for 24 h.
[0070] (2) Isolation of exosomes from colostrum
[0071] Exosomes were prepared by continuous centrifugation at 4 °C. Bovine colostrum (obtained from Lee Sung-young Changbuk Ranch, 1-ro 20, Bongsangwan-dong, Gyeongsung-myeon, Changnyeong-gun, Gyeongnam, South Korea) was centrifuged at 5000 × g for 30 min and 12000 × g for 1 h using a high-speed centrifuge with a JA-14 rotor (Avanti JE, Beckman Coulter, USA). The supernatant was passed through a 40 μm filter (93040, SPL, South Korea) and stored at -80 °C until use. The filtered milk was centrifuged at 35,000 × g for 1 h and 70,000 × g for 3 h using an ultracentrifuge with a 45Ti rotor (Optima XE-100, BeckmanCoulter, USA). The solution was divided into three layers, and the middle layer was filtered through syringe filters with pore sizes of 0.8, 0.45 and 0.2 μm (16592-K, 16555-K, 16534-K, Sartorius Stedim Biotech, Germany). The precipitate believed to be exosomes was obtained by centrifugation at 100,000 × g for 1 h. The exosomes were resuspended in Dulbecco's phosphate buffered saline (DPBS, LB001, Welgene, South Korea) and rotated overnight at 4 ° C. The exosomes thus obtained are hereinafter referred to as colostrum-derived exosomes (Col-exo, Example 1).
[0072] To prepare exosome-free milk (Comparative Example 1), the clarified solution after removing the exosome precipitate was centrifuged at 200,000×g for 3 h to remove the remaining exosomes, and the supernatant was considered as exosome-free milk.
[0073] (3) Protein blotting
[0074] The concentration of exosome proteins was quantified using a BCA assay kit (23225, Thermofisher Scientific, USA), and the proteins were denatured with SDS-PAGE loading buffer. The samples were electrophoresed on sodium dodecyl sulfate (SDS) polyacrylamide gels. The separated proteins were transferred to a nitrocellulose membrane, and the membrane was blocked with 5% skim milk. The primary antibody was bound to the target protein for 24 h. The membrane was rinsed with tris-buffered saline, 0.1% Tween 20 detergent (TBST), and the proteins were displayed by incubation with HRP-labeled secondary antibodies for 40 min at room temperature. The displayed proteins were visualized using Clarity Western ECL substrate (1705061, Bio-Rad, USA).
[0075] The antibodies used were Alix (1:500, NB100-65678, Novus, USA), Tsg-101 (1:1000, ab83, Abcam, USA), CD9 (1:1000, NB500-494, Novus, USA), GM130 (1:500, PA1077, ThermofisherScientific, USA), goat anti-mouse IgG antibody (HRP) (1:1000, GTX21311-01, GeneTex, USA) and goat anti-rabbit IgG antibody (HRP) (1:1000, GTX21310-01, GeneTex, USA).
[0076] According to the results of Example 1 and Comparative Example 1, Figure 1a As shown, Alix, Tsg-101, and CD9, which are markers of exosomal proteins, were identified in Example 1. In contrast, GM130, which is a non-exosomal protein, was found in Comparative Example 1. These results indicate that the presence or absence of exosomes distinguishes Comparative Example 1 (milk without exosomes) from Example 1 (exosomes).
[0077] (4) Dynamic light scattering (DLS) and transmission electron microscopy (TEM)
[0078] For DLS, exosomes were diluted to 0.1 μg / μl with distilled water and transferred to disposable cuvettes (art.01960-00, Kartell LABWARE, Italy). The size distribution of exosomes was measured by DLS (Zetasizer NanoZS, Malvern Instruments, UK) at a fixed angle of 173°. For each sample, three independent measurements were performed and averaged for software analysis.
[0079] To confirm the TEM images, 10 μg of exosomes were deposited on a carbon-coated copper grid (CF200-Cu, Emgrid Australia, Australia) for 30 min at room temperature. For negative staining of exosomes, the copper grid was contrasted with uranyl acetate for one minute. The morphology of exosomes was observed by TEM (FEI Tecnai F20 G2, Philips, The Netherlands).
[0080] like Figure 1b and Figure 1c As shown, the exosomes of Example 1 had an average diameter of 85.2 nm and were found to be spherical.
[0081] (5) Cellular uptake of exosomes
[0082] Exosomes were labeled with 650 nM cyanine 5.5 NHS ester by rotating overnight at 4 °C. Unbound fragments were washed twice using Airfuge. Cells were plated at 2 × 10 RAW264.7 cells. 5 Cells / dish and NCM460 cells 3×10 5 The density of cells / dish was plated on a confocal culture dish. Exosomes were treated with each concentration (0.05 and 0.1 mg / ml) and washed with DPBS at each time point. To capture images, cells were fixed with formaldehyde and then 4',6-diamidino-2-phenylindole (DAPI) was added to stain nucleic acids for 15 min. Images were taken with a confocal microscope (Leica TCS SP6, Leica, Germany).
[0083] (6) Cell proliferation and viability analysis
[0084] Cell viability assays were performed according to the Cell Counting Kit-8 (CCK-8) (CK04, Dojindo, Japan) guidelines. NCM460 and RAW264.7 cells were seeded in 96-well plates at densities of 6,000 and 8,000 cells / well, respectively, and allowed to attach for 24 hours. Cells were treated with different concentrations of Comparative Example 1 (milk without exosomes) or the exosomes of Example 1 (0.5 mg / ml in the viability assay) for 24 hours. As an additional step for viability analysis, cells were incubated with 2.5% DSS (0216011080, MPBiomedicals, USA) solution (w / v) for 24 hours. The culture medium was replaced with serum-free medium containing 10% CCK-8 solution. The absorbance at a wavelength of 450 nm was measured with a microplate reader (SpectraMAX 340, Molecular Devices, USA). RAW264.7 cells were incubated with 100 ng / ml LPS and 20 ng / ml INF-γ for 24 h before treatment with exosomes.
[0085] The intracellular delivery efficiency of Example 1 (Col-exo) was studied. RAW264.7 cells were incubated with Example 1 labeled with Cy5.5 at a concentration of 0.05 or 0.1 mg / ml for 0, 1, 4, 8, 12 or 24 h ( Figure 2a ).exist Figure 2a In the figure, the darker small circles represent DAPI and the brighter circles represent Col-exo. Confocal images show that significant intracellular uptake of Example 1 (Col-exo) occurs within 8 hours, and the images show that uptake is saturated within 24 hours. In addition, NCM460 cells show a similar pattern. Based on these data, the uptake time of Example 1 (Col-exo) was set to 24 hours in subsequent in vitro and in vivo experiments.
[0086] Next, to investigate the relationship between Example 1 (Col-exo) and cell growth, cell proliferation assays were performed on NCM460 cells and RAW264.7 cells ( Figure 2b ). It can be seen that when NCM460 cells were treated with Example 1 (Col-exo) at a concentration of 0.1 mg / ml, cell proliferation increased significantly to 113.1±3.4%. In Example 1, this cell proliferation remained almost unchanged until the concentration was 1 mg / ml. Another cell line RAW264.7 showed a significant increase in cell growth at a concentration of 0.5 mg / ml, especially at a concentration of 1 mg / ml, it increased to 121.8±4.7%.
[0087] In addition, the ability of Example 1 (Col-exo) to repair external damage after damaging colon epithelial cells with dextran sulfate sodium (DSS, 36,000-50,000 Da), a chemical that causes inflammatory bowel disease (IBD), was observed ( Figure 2c ). Treatment with 2.5% DSS for 24h caused cell damage, resulting in a decrease in cell growth rate to 82.7±3.7%. The group treated with Example 1 (milk without exosomes) showed a similar level of cell viability as that treated with DSS, whereas Example 1 (Col-exo) was able to restore cell viability to 91.8±2.6%. As a result, it was found that Example 1 (Col-exo) increased the proliferation of NCM460 and RAW264.7 cells.
[0088] (7) Confirmation of anti-inflammatory effects
[0089] Next, DCF-DA was used to determine whether bovine colostrum-derived exosomes could reduce the intracellular reactive oxygen species (ROS) concentration. RAW264.7 cells were cultured at 2 × 10 5 The cells were seeded in confocal culture dishes at a density of 3 × 10 and treated with 100 ng / ml LPS and 20 ng / ml IFN-γ for 24 h to induce M1 macrophages. 5 The cells were cultured at a density of 100 μg / ml per well for 24 h. Each cell was treated with exosome-free milk or exosomes at a concentration of 0.1 mg / ml for 24 h. Oxidative stress was induced by providing 100 μM H2O2 for 30 min and incubating the cells with 50 μM 2',7'-dichlorofluorescein diacetate (DCFDA) for 30 min. After washing the cells with DPBS, fluorescence images were obtained using a confocal microscope.
[0090] like Figure 3aAs shown, in NCM460 cells and RAW264.7 cells, the intracellular ROS level (light circles) of the group treated with Example 1 (Col-exo) was significantly reduced compared with the group treated with hydrogen peroxide or the group treated with Control Example 1 (milk without exosomes).
[0091] (8) Quantification of cytokine levels in vitro
[0092] In addition, the expression levels of mRNA encoding intracellular cytokines involved in inflammatory responses were analyzed. 5 Cells / ml) were plated in culture dishes and stimulated with 100 ng / ml LPS and 20 ng / ml IFN-γ for 24 h. M1-induced cells were treated with milk or exosomes without exosomes for 24 h and then washed twice with DPBS. Total RNA was extracted with TrizolTM reagent according to the manufacturer's guidelines, and cDNA was generated with oligo(dT) primers after reverse transcription. Quantification of cytokines was performed by quantitative real-time PCR (qRT-PCR) using SYBR Green qPCR premix (RT501S, enzynomics, Korea) and respective primers (Table 1), and PCR cycles were set according to the premix protocol.
[0093]
Table 1
[0094]
[0095] First, RAW264.7 cells were differentiated into M1 macrophages and treated with Example 1 (Col-exo) and Comparative Example 1 (milk without exosomes). Figure 3b As shown, quantitative real-time PCR (qRT-PCR) data showed that the mRNA expression levels of tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) in Example 1 were reduced by 0.69 times and 0.61 times, respectively, compared with the control group. In contrast, the mRNA expression level of interleukin-10 (IL-10), an anti-inflammatory cytokine, in the Example 1 (Col-exo) group increased by 1.7 times compared with the control group. Therefore, it was found that Example 1 has an anti-inflammatory effect at the cellular level.
[0096] (9) In vitro biodistribution of colostrum-derived exosomes
[0097] Prior to confirming the effect of Example 1 (Col-exo) in a colitis mouse model, relative biodistribution in organs was measured after oral administration of Cy5.5-labeled Example 1 (Col-exo). Cy5.5-labeled exosomes were orally administered to BALB / c mice. Mice were fed by oral gastric tube, and after 5h and 24h, the gastrointestinal tract and other organs, including heart, lungs, spleen, kidneys and liver, were collected. The fluorescence intensity of isolated organs was assessed using an in vivo imaging system (IVIS) (Lumina Series III Perkin Elmer, USA). The uptake of exosomes was observed in formalin-fixed, paraffin-embedded gastrointestinal organs. Paraffin-embedded tissues were cut into 5μm thick slices. Representative images were captured using a confocal microscope.
[0098] Results, such as Figure 4a As shown in Figure 2, when the fluorescence intensity was measured 5 h after feeding with Cy5.5-labeled Col-exo, it showed a strong signal in the gastrointestinal tract, especially in the colon. In addition, it was confirmed that the fluorescence signal was significantly maintained in the stomach and colon at the 24 h time point. Figure 4b As can be seen in the figure, the stomach, small intestine, and colon were sliced, and the uptake of Example 1 (Col-exo) labeled with Cy5.5 was observed in the organs. The uptake of Example 1 (Col-exo) labeled with Cy5.5 was mainly found in the stomach and colon. After 24 hours, it was confirmed that the uptake of exosomes was significantly reduced. Therefore, Example 1 was orally administered to mice every day.
[0099] (10) Evaluation of inflammatory response in colitis mouse model
[0100] Eight-week-old BALB / c female mice (Orient Bio, Korea) were used for the ulcerative colitis model. The mice were randomly divided into three groups, healthy control (normal saline), DSS-induced colitis (DSS), and Col-exo pretreatment (Example 1), and underwent a 10-day environmental adaptation period. The Example 1 (Col-exo) group was pretreated with 1 mg of colostrum-derived exosomes per day for one week by oral gastric tube feeding, while the other groups were given saline only. Inflammatory bowel disease (IBD) was chemically induced by randomly administering 2.5% DSS solution in drinking water for one week. On day 27, the mice were sacrificed and the colon length ( Figure 4c ).
[0101] 1) Disease Activity Index (DAI)
[0102] From day 18 to day 27, the disease activity index was evaluated daily by three independent observers for each mouse based on weight loss, stool viscosity, and fecal bleeding characteristics (Table 2). The total score ranged from 0 to 12, with higher scores indicating more severe disease.
[0103]
Table 2
[0104]
[0105]
[0106] Animal experiments were performed according to the established protocol, and the results showed that, in contrast to the DSS group (which showed rapid weight loss), the Example 1 (Col-exo) group effectively suppressed the weight loss of DSS-induced colitis mice. Figure 4d 2) In vitro ROS imaging
[0107] On the 27th day, L-012 (120-04891, Fujifilm Wako Chemicals, Japan) was prepared by dissolving in DPBS and stored in a dark compartment at room temperature. L-012 solution was injected intraperitoneally at a dose of 20 mg / kg, and the colon of the mice was separated after 15 min. ROS in the isolated colon were imaged by an in vivo imaging system (IVIS) (Lumina Series III Perkin Elmer, the United States). The data show the average irradiation efficiency (p / s / cm2 / sr) measured for 5 min.
[0108] Animal experiments were performed according to the established protocol, and the results showed that, in contrast to the DSS group (which showed rapid weight loss), the Example 1 (Col-exo) group effectively suppressed the weight loss of DSS-induced colitis mice. In addition, the disease activity index (DAI) score of the Example 1 (Col-exo) group was significantly lower than that of the DSS group. The colon length of the Example 1 (Col-exo) group was significantly longer than that of the DSS group and recovered to a level similar to that of the saline group ( Figure 4d ). Through the above experiments, it was confirmed that Example 1 alleviated DSS-induced colitis.
[0109] (11) Histological analysis
[0110] Isolated mouse colon tissue was prepared using the Swiss-roll technique. Colon samples were fixed overnight in formalin, dehydrated, and embedded in paraffin. All tissue specimens were cut into 5 μm thick sections.
[0111] 1) H&E (Hematoxylin and Eosin)
[0112] The sections were dewaxed in xylene and stained with hematoxylin. After rinsing with tap water, nuclear staining with bluing agent was completed. Proteins were nonspecifically stained with eosin (ab245880, Abcam, USA). The slides were fixed in toluene and observed with an optical microscope (BX51, Olympus Corporation, Japan).
[0113] As a result, severe surface epithelial damage, ulceration, and immune cell infiltration were found in the colon of the DSS group ( Figure 5a ). In contrast, the Example 1 group showed slight epithelial hyperplasia.
[0114] 2) Immunohistochemistry (IHC)
[0115] Because COX-2 is a key molecule that triggers inflammation, immunohistochemistry (IHC) is used to detect the expression level of COX-2 protein in each group. According to the manufacturer's protocol, mouse and rabbit specific HRP / DAB (ABC) detection IHC kits (ab64264, Abcam, USA) were used to detect the expression of COX-2 in colon tissue. The target protein was labeled with a COX-2 antibody (1:500, ab15191, Abcam, USA) in PBS containing 1% BSA and 0.5% TritonX-100. Tissue sections were stained with DAB substrate and counterstained with hematoxylin. These images were taken with an optical microscope.
[0116] like Figure 5b As shown, the expression of COX-2 protein in the colon of the Example 1 (Col-exo) group was reduced compared with that of the DSS group.
[0117] 3) Immunofluorescence (IF)
[0118] To observe the extent of tissue cell death, TUNEL assay was performed according to the manufacturer's instructions of the fluorescent TUNEL system (G3250, Promega, USA). That is, the rehydrated tissue sections were fixed with formaldehyde and permeabilized by adding proteinase K solution. Formaldehyde fixation was repeated and incubated with equilibration buffer. The apoptotic area was marked with terminal deoxynucleotidyl transferase (TdT) reaction and counterstained with DAPI.
[0119] like Figure 5c As shown in the TUNEL staining data, cell death of colon cells occurred severely in the DSS group and was mostly recovered in the Example 1 (Col-exo) group. As a result, Example 1 effectively reduced the severity of colitis and cell death.
[0120] (12) Quantification of cytokine levels in vivo
[0121] To confirm the effect of Col-exo in reducing colon inflammation, ROS levels in the colon were measured using a luminol-based chemiluminescent probe. Mouse colon tissue was homogenized using a homogenizer (HG-15D, Wise Tis, South Korea) with TrizolTM reagent. After homogenization, total RNA was obtained from colon tissue according to the operating manual of TrizolTM reagent. After cDNA synthesis, qRT-PCR was performed using SYBR Green (RT501M, Enzynomics, South Korea) according to the manufacturer's protocol. All qRT-PCRs were performed using QuantStudioTM1 real-time PCR instrument (Applied Biosystems, USA). Each primer is summarized in (Table 1).
[0122] As a result, it was found that the ROS level was significantly increased in the DSS group, while it was reduced by less than half in the Example 1 (Col-exo) group ( Figure 6a ).
[0123] (13) Confirmation of improvement in intestinal inflammation
[0124] Next, in order to confirm the effect of Col-exo on improving intestinal inflammation, immunofluorescence (IF) was used to confirm the expression of iNOS protein, which is a marker of proinflammatory M1 macrophages. Macrophage infiltration in mouse colon tissue was detected by iNOS staining. The dewaxed tissue was rehydrated and boiled in antigen retrieval buffer (citrate buffer pH 6.0) (ab93678, Abcam, USA). The slides were washed with PBS, 0.05% Tween 20 detergent (PBST) and blocked at room temperature for 10 min with PBST containing 5% BSA (w / v). Alexa fluor 488-conjugated iNOS monoclonal antibody (53-5920-82, eBiosience, USA) prepared in PBS containing 1% BSA (w / v) and 0.5% Triton-100 (v / v) was used to stain sections overnight at 4 ° C. Nucleic acids were stained with DAPI for 15 min at room temperature. The slides were fixed with water-soluble fixing solution (0100-01, Southern Biotech, USA) and photographed under a confocal microscope. Figure 6b As shown, iNOS protein was overexpressed in the DSS group, whereas it was hardly observed in the Example 1 (Col-exo) group.
[0125] In addition, qRT-PCR was used to detect the mRNA expression of inflammatory cytokines ( Figure 6c). The qRT-PCR results showed that the mRNA levels of TNF-α and IL-6 in the DSS group increased by 3.8 times and 3.6 times, respectively, compared with the saline group. In contrast, their mRNA expression levels were similar to those in the saline group. However, the qRT-PCR results of anti-inflammatory cytokines showed an opposite trend, with IL-10 mRNA expression in the DSS group decreasing by about 20 times compared with the saline group. It is worth noting that the IL-10 expression level in the Example 1 (Col-exo) treatment group slightly recovered to a level approximately 5 times that of the DSS treatment group. These results indicate that Example 1 reduced excessive intestinal inflammatory responses.
[0126] (14) Statistical analysis
[0127] Statistical analysis of the data was performed using Prism 8.0 with parametric one-way ANOVA analysis and two-way ANOVA analysis. All results are expressed as mean ± standard deviation. All graphs were constructed in Prism 8.0 (GraphPad Software Inc, USA).
[0128] 2. Therapeutic effect of RNA-encapsulated milk-derived exosomes on inflammatory bowel disease
[0129] (1) Extraction of exosomes
[0130] Commercial pasteurized milk was used, and the extraction of exosomes was performed using the same method as described in Example 1.(2).
[0131] (2) Confirmation of the stability of exosomes during electroporation
[0132] 0.1 mg / ml of cell-derived exosomes (HEK exosomes) and milk-derived exosomes (milk exosomes) were electroporated at 300 V, 30 ms, 5 pulses, 1 s intervals, and incubated at 4° C. for 3 h. The size changes of exosomes before and after electroporation were observed using the same method as the dynamic light scattering (DLS) experiment in Example 1. (4).
[0133] Results, such as Figure 7 As shown in the figure, it was confirmed that the size of cell-derived exosomes decreased after electroporation, while the size distribution of milk-derived exosomes remained almost unchanged before and after electroporation.
[0134] (3) siRNA encapsulation
[0135] After micropores were generated in the exosomes by electroporation, TNF-α siRNA was mixed into the exosome solution to encapsulate TNF-α siRNA inside the exosomes, and then siRNA not encapsulated inside the exosomes was removed using ribonuclease. Exosomes that did not undergo electroporation, exosomes that underwent electroporation, the resulting mixture of TNF-α siRNA in exosomes that did not undergo electroporation, and exosomes encapsulated with TNF-α siRNA mixed in exosomes that underwent electroporation were loaded onto a 1% agarose gel and electrophoresed at 100 V for 10 min in an electrophoresis apparatus. Then, visual confirmation was performed using a gel image analyzer. As a result, it was confirmed that TNF-α siRNA was effectively encapsulated inside the exosomes when the exosomes were subjected to electroporation, as shown in FIG. Figure 8 Hereinafter, the exosomes encapsulated with TNF-α siRNA will be referred to as Example 2, and the exosomes not encapsulated with TNF-α siRNA will be referred to as Comparative Example 2.
[0136] (4) Comparison of siRNA encapsulation efficiency according to electroporation variables
[0137] To confirm the voltage conditions, for 0.1 mg / ml of milk-derived exosomes, 5 electroporations and an electroporation time of 30 ms were fixed, and voltages of 200, 250, 300, 350, and 400 V were applied to compare the encapsulation efficiency of TNF-α siRNA. To confirm the number of electroporation conditions, a voltage of 300 V and an electroporation time of 30 ms were fixed, and when 1, 2, 3, 4, and 5 electroporations were applied, the encapsulation efficiency of TNF-α siRNA was compared, and to confirm the time conditions of electroporation, a voltage of 300 V and 5 electroporations were fixed, and when the electric shock was applied for 10, 20, 30, 40, 50, and 60 ms, the encapsulation efficiency of TNF-α siRNA was compared. When electroporation was applied 5 times at 300 V for 30 ms, it was confirmed that TNF-α siRNA was most effectively encapsulated into exosomes ( Fig. 9 ).
[0138] (5) Visualization of milk-derived exosomes encapsulated with TNF-α siRNA
[0139] The milk-derived exosomes were subjected to electric shocks of 300 V, 30 ms, 5 pulses and 1 s intervals, and then encapsulated with TNF-α siRNA (FAM labeled) and incubated for 3 h, and the milk-derived exosomes were labeled with Cy5.5. The milk-derived exosomes encapsulated with TNF-α siRNA (Example 2) were mixed with Fluoromount-G solution and fixed on a glass slide. Then, the milk-derived exosomes encapsulated with TNF-α siRNA (Example 2) were measured and visualized in the x, y and z directions by super-resolution microscopy (SRM). Fig.10a), and plot the relative fluorescence area ( Fig.10b ). When reviewing the data after TNF-α siRNA encapsulation, it was confirmed that in Example 2, the TNF-α siRNA labeled with green (dark gray in the figure) FAM was located at the center of the exosomes labeled with red (white in the figure) Cy5.5. In addition, in the relative fluorescence area, it was confirmed that when TNF-α siRNA was encapsulated, Cy5.5, which showed a fluorescence area of 100 or more in Comparative Example 2 with only exosomes, was reduced to 100 or less, and the fluorescence area labeled with FAM increased relatively. This means that TNF-α siRNA is not carried on the surface of the exosomes by methods such as adhesion, but enters and is encapsulated in the middle of the internal area of the exosomes precisely through the micropores generated by electroporation.
[0140] (6) Confirmation of cellular uptake of milk-derived exosomes encapsulating TNF-α siRNA
[0141] Pores were formed in the milk-derived exosomes by the same electroporation method as in Example 2, but the milk-derived exosomes were encapsulated with Cy3-labeled TNF-α siRNA and incubated for 3 h. Then, NCM460 cells were treated with exosomes, and the extent of cellular uptake was observed by confocal microscopy after 24 h. Fig.11 As shown (dark gray in the figure represents DPAI, and light dots represent siRNA), it can be seen that compared with the case where cells were treated with TNF-α siRNA alone, the introduction into cells occurred effectively in Example 2, wherein TNF-α siRNA was encapsulated in exosomes.
[0142] (7) Confirmation of the intracellular delivery rate of milk-derived exosomes encapsulating TNF-α siRNA by electroporation
[0143] Pores were formed in milk-derived exosomes by the same electroporation method as in Example 2, and Cy3-labeled TNF-α siRNA was encapsulated and stabilized at 4°C for 3 h. RAW264.7 cells were cultured at 3×10 5 The density of cells / dish was plated on a confocal culture dish. Lipofectamin was used as a control to transfect TNF-α siRNA. RAW264.7 cells were treated with the control and Example 2, respectively. After 24 hours, the cells were washed with DPBS, fixed in formaldehyde, and the nuclei were stained with Hoechst33342 for 10 minutes. The relative fluorescence intensity of the stained cells was photographed using a confocal microscope (n=4). The fluorescence intensity of the photographed images was measured using the Image J program.
[0144] like Fig.12As shown in the figure (dark gray represents Hoechst, and light gray represents TNF-si-RNA), the relative TNF-α siRNA fluorescence intensity in the control-treated cells was set to 100 (Lipofectamin: 100±17.19), which was set to 100% intracellular delivery rate. In contrast, the relative TNF-α siRNA fluorescence intensity in the cells treated with Example 2 showed about 75% (Example 2: 75.04±11.25). That is, it can be seen that the intracellular delivery rate of Example 2 is about 75% (t-test: ns).
[0145] (8) Confirmation of the gene silencing effect of milk-derived exosomes encapsulated with TNF-α siRNA (in vitro)
[0146] The same conditions as the electroporation method were used to form pores on the milk-derived exosomes, and the milk-derived exosomes and TNF-α siRNA were mixed at a ratio of 1 mg:14 μg and incubated for 3 h. RAW264.7 cells pre-activated with LPS (1 μg / ml, 24 h) were treated with milk-derived exosomes encapsulated with TNF-α siRNA (Example 2) at different concentrations. After 24 h, TNF-α mRNA levels were measured by qRT-PCR. As a result, it was confirmed that the expression of TNF-α mRNA decreased in a concentration-dependent manner ( Fig.13 ).
[0147] (9) Confirmation of anti-inflammatory effects (in vivo)
[0148] Inflammatory bowel disease (IBD) animal model (BALB / c, female, 8 weeks) was induced with DSS 2.5%. Milk-derived exosomes (Comparative Example 2) and milk-derived exosomes encapsulated with TNF-α siRNA (Example 2) were intraperitoneally injected at intervals of 3 days, and the weight change and disease activity index (DAI) were measured ( Fig.14a ). The scoring table is shown in Table 2. In addition, the intestinal length and colon tissue were observed by H&E, and the H&E experimental method was the same as that of Example 1. (12).
[0149] It was confirmed that intraperitoneal injection of Example 2 at 3-day intervals resulted in weight loss, which is typical in the IBD model ( Fig.14b ), and it can be seen that milk-derived exosomes encapsulated with TNF-α siRNA have an IBD inflammatory therapeutic effect ( Fig.14c ).
[0150] Implementation
[0151] - Embodiment 1: A composition for improving intestinal health function, comprising: milk-derived exosomes; and a therapeutic agent, wherein the therapeutic agent is DNA, RNA or a small molecule, and the therapeutic agent is positioned and encapsulated in the space inside the exosomes.
[0152] - Embodiment 2: The composition of embodiment 1, wherein the composition has an intracellular delivery rate of 60% to 90%.
[0153] - Embodiment 3: The composition of any one of embodiments 1 or 2, wherein the milk is milk or colostrum of human, cow, sheep, goat, goat, camel, buffalo or yak origin.
[0154] - Embodiment 4: The composition of any one of Embodiments 1 to 3, wherein the RNA is one or more RNAs selected from the group consisting of siRNA, miRNA, mRNA, shRNA, ncRNA and antisense RNA.
[0155] - Embodiment 5: The composition of Embodiment 4, wherein the siRNA is one or more siRNAs selected from the group consisting of TNF-α siRNA, TGF-β siRNA, JAK3 siRNA and IL-6R siRNA.
[0156] - Embodiment 6: The composition of Embodiment 4, wherein the miRNA is one or more miRNAs selected from the group consisting of Let-7b-5p, miR-320a-3p and miR-21.
[0157] - Embodiment 7: The composition of any one of Embodiments 1 to 6, wherein the composition is a liquid preparation and comprises milk-derived exosomes encapsulating the therapeutic agent at a concentration of 100 to 1000 μg / ml.
[0158] - Embodiment 8: The composition of any one of Embodiments 1 to 7, wherein the composition is a lyophilized preparation and comprises milk-derived exosomes encapsulating 0.001 to 100 wt % of the therapeutic agent based on the total weight of the composition.
[0159] - Embodiment 9: The composition according to any one of Embodiments 1 to 8, wherein the composition is administered orally.
[0160] Embodiment 10: A method for preparing the composition of any one of embodiments 1 to 9, comprising the following steps: (a) isolating exosomes from milk; (b) forming micropores on the surface of the exosomes by electroporating the isolated exosomes; (c) mixing the electroporated exosomes in step (b) with a therapeutic agent; and (d) removing the therapeutic agent not encapsulated in the exosomes.
[0161] - Embodiment 11: The method of Embodiment 10, wherein the electroporation in step (b) applies a voltage of 250 to 350 V.
[0162] - Embodiment 12: The method according to any one of Embodiments 10 to 11, wherein the electroporation in step (b) is performed with 3 to 7 pulses.
[0163] - Embodiment 13: The method according to any one of Embodiments 10 to 12, wherein the electroporation of step (b) applies pulses with a time period of 20 to 40 ms.
[0164] - Embodiment 14: The method of any one of Embodiments 10 or 13, wherein the milk of step (a) is milk or colostrum of human, cow, sheep, goat, goat, camel, buffalo or yak origin.
[0165] - Embodiment 15: The method of any one of Embodiments 10 to 14, wherein the therapeutic agent in step (c) is DNA, and wherein step (d) is the addition of a deoxyribonuclease to remove unencapsulated therapeutic agent.
[0166] - Embodiment 16: The method of any one of Embodiments 10 to 15, wherein the therapeutic agent in step (c) is RNA, and wherein step (d) is the addition of a ribonuclease to remove unencapsulated therapeutic agent.
[0167] - Embodiment 17: The method of Embodiment 16, wherein the RNA is one or more RNAs selected from the group consisting of siRNA, miRNA, mRNA, shRNA, ncRNA and antisense RNA.
[0168] - Embodiment 18: The method of Embodiment 17, wherein the siRNA is one or more siRNAs selected from the group consisting of TNF-α siRNA, TGF-β siRNA, JAK3 siRNA and IL-6R siRNA.
[0169] Embodiment 19: The method of Embodiment 17, wherein the miRNA is one or more miRNAs selected from the group consisting of Let-7b-5p, miR-320a-3p and miR-21.
Claims
1. A composition for improving intestinal health function, comprising: Milk-derived exosomes; and therapeutic agents, wherein the therapeutic agent is DNA, RNA or a small molecule, and The therapeutic agent is located and encapsulated in the space inside the exosomes. The composition according to claim 1 , wherein the composition has an intracellular delivery rate of 60% to 90%.
3. The composition according to claim 1, wherein the milk is milk or colostrum of human, cow, sheep, goat, goat, camel, buffalo or yak origin. 4 . The composition according to claim 1 , wherein the RNA is one or more RNAs selected from the group consisting of siRNA, miRNA, mRNA, shRNA, ncRNA and antisense RNA. The composition according to claim 4 , wherein the siRNA is one or more siRNAs selected from the group consisting of TNF-α siRNA, TGF-β siRNA, JAK3 siRNA and IL-6R siRNA. The composition according to claim 4 , wherein the miRNA is one or more miRNAs selected from the group consisting of Let-7b-5p, miR-320a-3p and miR-21. 7 . The composition according to claim 1 , wherein the composition is a liquid preparation and comprises milk-derived exosomes encapsulating the therapeutic agent at a concentration of 100 to 1000 μg / ml. 8 . The composition according to claim 1 , wherein the composition is a lyophilized preparation and comprises milk-derived exosomes encapsulating 0.001 to 100 wt % of the therapeutic agent based on the total weight of the composition.
9. The composition of claim 1, wherein the composition is administered orally.
10. A method for preparing the composition of any one of claims 1 to 9, comprising the steps of: (a) Isolation of exosomes from breast milk; (b) forming micropores on the surface of exosomes by electroporating the isolated exosomes; (c) mixing the electroporated exosomes in step (b) with a therapeutic agent; and (d) Removal of therapeutic agents not encapsulated within exosomes.
11. The method according to claim 10, wherein the electroporation in step (b) applies a voltage of 250 to 350 V.
12. The method according to claim 10, wherein the electroporation in step (b) is performed with 3 to 7 pulses.
13. The method of claim 10, wherein the electroporation in step (b) applies pulses with a time period of 20 to 40 ms.
14. The method according to claim 10, wherein the milk in step (a) is milk or colostrum from humans, cows, sheep, goats, goats, camels, buffaloes or yaks.
15. The method of claim 10, wherein the therapeutic agent in step (c) is DNA, and Wherein step (d) is to add deoxyribonuclease to remove the unencapsulated therapeutic agent.
16. The method of claim 10, wherein the therapeutic agent in step (c) is RNA, and Wherein step (d) is to add ribonuclease to remove the unencapsulated therapeutic agent.
17. The method according to claim 16, wherein the RNA is one or more RNAs selected from the group consisting of siRNA, miRNA, mRNA, shRNA, ncRNA and antisense RNA.
18. The method according to claim 17, wherein the siRNA is one or more siRNAs selected from the group consisting of TNF-α siRNA, TGF-β siRNA, JAK3 siRNA and IL-6R siRNA.
19. The method of claim 17, wherein the miRNA is one or more miRNAs selected from the group consisting of Let-7b-5p, miR-320a-3p, and miR-21.
